scholarly journals Interleukin-5 (IL-5) increases spontaneous apoptosis of B-cell chronic lymphocytic leukemia cells in vitro independently of bcl-2 expression and is inhibited by IL-4

Blood ◽  
1994 ◽  
Vol 84 (7) ◽  
pp. 2297-2304 ◽  
Author(s):  
T Mainou-Fowler ◽  
VA Craig ◽  
JA Copplestone ◽  
MD Hamon ◽  
AG Prentice

Abstract During hematopoiesis, viability factors that suppress apoptosis are required throughout the differentiation process. Some of these factors may also function as growth factors. Interleukin-5 (IL-5) is recognized as a growth factor in hematopoiesis. We examined the involvement of IL- 5 as a viability factor of B-CLL in vitro. In 13 B-CLL cases studied, IL-5 at 20 U/mL increased spontaneous apoptosis by a mean percentage of 53% (range, 20% to 129%) (P < .05) after 2 days in culture. On the third day, the mean percentage increase was 37% (range, 18% to 50%). In all cases, IL-4 protected B-CLL cells against IL-5-induced apoptosis by a mean percentage of 47% (range, 18% to 81%) (P < .001). This protection was specific to IL-4 and it was reduced with anti-IL-4 antibody. In addition, expression of bcl-2 protein in untreated cultures was not significantly different from that of the IL-5-treated cells; mean equivalent of soluble fluorochrome (MESF) was 5.2 (range, 3.0 to 6.8) and 4.9 (range, 3.0 to 6.3), respectively (P > .2). In freshly isolated B-CLL cells, the MESF was 4.5 (range, 2.4 to 6.6). These results show that IL-5 induced apoptosis in B-CLL cells by a pathway that is independent of bcl-2 expression. IL-4 partially protects against this effect.

Blood ◽  
1994 ◽  
Vol 84 (7) ◽  
pp. 2297-2304 ◽  
Author(s):  
T Mainou-Fowler ◽  
VA Craig ◽  
JA Copplestone ◽  
MD Hamon ◽  
AG Prentice

During hematopoiesis, viability factors that suppress apoptosis are required throughout the differentiation process. Some of these factors may also function as growth factors. Interleukin-5 (IL-5) is recognized as a growth factor in hematopoiesis. We examined the involvement of IL- 5 as a viability factor of B-CLL in vitro. In 13 B-CLL cases studied, IL-5 at 20 U/mL increased spontaneous apoptosis by a mean percentage of 53% (range, 20% to 129%) (P < .05) after 2 days in culture. On the third day, the mean percentage increase was 37% (range, 18% to 50%). In all cases, IL-4 protected B-CLL cells against IL-5-induced apoptosis by a mean percentage of 47% (range, 18% to 81%) (P < .001). This protection was specific to IL-4 and it was reduced with anti-IL-4 antibody. In addition, expression of bcl-2 protein in untreated cultures was not significantly different from that of the IL-5-treated cells; mean equivalent of soluble fluorochrome (MESF) was 5.2 (range, 3.0 to 6.8) and 4.9 (range, 3.0 to 6.3), respectively (P > .2). In freshly isolated B-CLL cells, the MESF was 4.5 (range, 2.4 to 6.6). These results show that IL-5 induced apoptosis in B-CLL cells by a pathway that is independent of bcl-2 expression. IL-4 partially protects against this effect.


2007 ◽  
Vol 48 (2) ◽  
pp. 311-320 ◽  
Author(s):  
Burhan Turgut ◽  
Ozden Vural ◽  
Funda S. Pala ◽  
Gülsüm E. Pamuk ◽  
Kiymet TabakcioĞlu ◽  
...  

Blood ◽  
2012 ◽  
Vol 120 (21) ◽  
pp. 2887-2887
Author(s):  
Manoj Kumar Kashyap ◽  
Deepak Kumar ◽  
Harrison Jones Jones ◽  
Michael Y. Choi ◽  
Johanna Melo-Cardenas ◽  
...  

Abstract Abstract 2887 Chronic lymphocytic leukemia (CLL) remains incurable despite advances in the biology and treatment of this disease. Current data support the notion that resistance to therapy is promoted by a “protective” tumor microenvironment in which non-leukemia cells produce factors that enhance the resistance of CLL cells to spontaneous or drug-induced apoptosis. One such factor is the chemokine CXCL12, which interacts with its receptor CXCR4 on CLL cells to promote cancer cell survival. To examine the therapeutic potential of blocking CXCL12-CXCR4 interactions, we studied the effect of BMS-936564, a fully human IgG4 anti-CXCR4 antibody, using an in vitro co-culture model of human bone marrow derived stomal-NKter cells – leukemia cell interaction. Such stromal-NKter cells secrete CXCL12 and enhance the resistance of CLL cells to apoptosis in vitro. We observed that primary CLL cells co-cultured with stromal-NKter cells had significantly greater viability than CLL cells cultured alone (20–60% above baseline at 48 hours). Moreover, CLL cells co-cultured with stromal cells had enhanced resistance to drug-induced apoptosis. We found that BMS-936564 antibody at concentrations of 2–200nM could enhance the rate of apoptosis of CLL cells cultured alone or in the presence of stromal cells. CLL cells that expressed unmutated IgVH genes or ZAP-70 appeared equally susceptible to treatment with BMS-936564 as did CLL cells that lack these adverse prognostic markers, as did CLL cells that harbored deletions in 17p13.2 and that were resistant to chemotherapeutic agents, such a fludarabine monophosphate. BMS-936564 antibody inhibited CXCL12 mediated F-Actin polymerization in CLL cells at lower concentrations (20–200nM) compared to AMD-3100 (Mozobil), a small molecule CXCR4 inhibitor (50–150μM). In addition, AMD-3100 did not induce apoptosis in CLL cells (10–300μM). In summary, we observed that the anti-CXCR4 antibody BMS-936564 inhibited CXCL12 mediated activation of the CXCR4 receptor in CLL cells and induced apoptosis in leukemia cells. The pro-apoptotic activity of BMS-936564 was observed in cells cultured alone or together with stromal cells suggesting that this antibody had direct cytotoxic effect on leukemia cells and that it can overcome the protective tumor microenvironment. More over, the activity of BMS-936564 was independent of the presence of poor prognostic factors such as del(17p) suggesting that its mechanism of action is P53 independent. These findings show evidence that the CXCR4-CXCL12 pathway is a valid therapeutic target in CLL and provide additional biological rationale for ongoing clinical trials in CLL and other hematological malignancies using BMS-936564. Disclosures: Kuhne: Bristol-Myers Squibb: Employment. Sabbatini:Bristol-Myers Squibb: Employment. Cohen:Bristol-Myers Squibb: Employment. Shelat:Bristol-Myers Squibb: Employment. Cardarelli:Bristol-Myers Squibb: Employment. Kipps:Abbott: Consultancy, Research Funding.


Blood ◽  
2004 ◽  
Vol 104 (11) ◽  
pp. 4805-4805
Author(s):  
Tomoyuki Endo ◽  
Mitsufumi Nishio ◽  
Laura Rassenti ◽  
Arnon P. Kater ◽  
Thomas J. Kipps

Abstract A subset of blood mononuclear cells from patients with B-cell chronic lymphocytic leukemia (CLL) can differentiate into large, adherent cells, termed “nurse-like cells” (NLC), that can attract CLL cells and protect them from undergoing apoptosis in vitro. When removed from NLC in vitro, CLL cells often undergo spontaneous apoptosis. We observed that the relative viability of isolated CLL cells cultured without versus with NLC appeared constant for any one sample in different experiments and did not vary with the source of the NLC used in any one experiment. Furthermore, the isolated CLL cells from some patients could survive in vitro without NLC better than could the leukemia cells of other patients. We examined for characteristics associated with CLL cells that were more or less reliant on NLC for survival in vitro. For this, we defined CLL cell populations as having “low dependency” on NLC when the relative leukemia cell viability after two days culture without NLC was less than one half-log (33%) lower than that of the same CLL cells co-cultured with NLC. Using a Multiplex Ligation-dependent Probe Amplification (MLPA) assay, we examined CLL cell populations with low dependency (n = 4) versus samples with high dependency (n = 5) for expression of 40 distinct mRNA that encoded known pro-apoptotic or anti-apoptotic proteins. CLL cells with low dependency expressed significantly higher levels of BCL-2, and significantly lower levels of BAX-2 than CLL cells with high NLC dependency. There was no significant difference between the mean white blood cell counts of patients whose CLL cells had low-dependency versus those whose cells had high dependency on NLC in vitro. However, in the high dependency group there was a significantly higher proportion of cases that expressed ZAP-70 than in the group with low dependency. This association, however, could reflect the fact that many of the samples with low dependency were acquired from patients who had long-established disease, a characteristic that typically was not associated with patients who have CLL cells that expressed ZAP-70. The mean time from diagnosis to the date of sample collection was significantly longer (m = 66.6 ± 47.0 months, median = 49 months, n=30) for samples with low dependency than it was for those cases with high dependency (m = 41.2 ± 25.1 months, median = 39.5 months, n=20) (p=0.017). Furthermore, evaluation of serial samples collected over years from the same patients (n = 5) revealed that the relative dependency of CLL cells on NLC could decrease significantly over time. In none of the serial samples did we observe increased dependency of the CLL cells on NLC over time or over that observed for the CLL cells isolated from the initial sample collection. These data suggest that over the course of the disease CLL cells might acquire less dependency on NLC, and potentially also on its stromal microenvironment.


Sign in / Sign up

Export Citation Format

Share Document